Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
YANCHANG PETRO
00346
| (Q3)Dec 31, 2025 | (Q2)Sep 30, 2025 | (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q4)Mar 31, 2025 | (Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -20.69%83.05K | 30.67%112.04K | 39.09%72.88K | 56.60%381.59K | 46.40%138.74K | 73.74%104.71K | 24.08%85.74K | 171.99%52.4K | 90.21%243.68K | 98.63%94.77K |
| Selling and administrative expenses | -10.75%18K | -20.59%22.13K | -20.15%18.72K | -18.97%107.27K | -17.99%35.78K | -37.13%20.17K | -32.41%27.87K | 51.96%23.45K | 26.17%132.38K | -0.17%43.63K |
| -General and administrative expense | -10.75%18K | -20.59%22.13K | -20.15%18.72K | -18.97%107.27K | -17.99%35.78K | -37.13%20.17K | -32.41%27.87K | 51.96%23.45K | 26.17%132.38K | -0.17%43.63K |
| Other operating expenses | -23.06%65.05K | 55.36%89.91K | 87.06%54.16K | 146.47%274.32K | 101.32%102.95K | 199.94%84.54K | 107.69%57.87K | 654.92%28.95K | 379.88%111.3K | 1,175.60%51.14K |
| Operating profit | 20.69%-83.05K | -30.67%-112.04K | -39.09%-72.88K | -56.60%-381.59K | -46.40%-138.74K | -73.74%-104.71K | -24.08%-85.74K | -171.99%-52.4K | -90.21%-243.68K | -98.63%-94.77K |
| Net non-operating interest income (expenses) | -74.05%1.5K | -72.85%2.12K | -67.61%3.06K | 59.87%26.92K | -64.04%3.88K | 0.14%5.79K | 7.8K | 9.46K | 16.84K | 10.79K |
| Non-operating interest income | -74.05%1.5K | -72.85%2.12K | -67.61%3.06K | 59.87%26.92K | -64.04%3.88K | 0.14%5.79K | --7.8K | --9.46K | --16.84K | --10.79K |
| Other net income (expenses) | 101.07%17 | -287.15%-3.16K | 259.03%3.2K | -1.59K | -817 | -2.01K | ||||
| Gain on sale of security | 101.07%17 | -287.15%-3.16K | 259.03%3.2K | ---- | ---- | ---1.59K | ---817 | ---2.01K | ---- | ---- |
| Income before tax | 18.89%-81.53K | -43.58%-113.09K | -48.21%-66.62K | -56.35%-354.67K | -55.31%-130.44K | -84.48%-100.52K | -13.98%-78.76K | -133.34%-44.95K | -77.06%-226.84K | -76.02%-83.98K |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | 18.89%-81.53K | -43.58%-113.09K | -48.21%-66.62K | -56.35%-354.67K | -55.31%-130.44K | -84.48%-100.52K | -13.98%-78.76K | -133.34%-44.95K | -77.06%-226.84K | -76.02%-83.98K |
| Net income continuous operations | 18.89%-81.53K | -43.58%-113.09K | -48.21%-66.62K | -56.35%-354.67K | -55.31%-130.44K | -84.48%-100.52K | -13.98%-78.76K | -133.34%-44.95K | -77.06%-226.84K | -76.02%-83.98K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 18.89%-81.53K | -43.58%-113.09K | -48.21%-66.62K | -56.35%-354.67K | -55.31%-130.44K | -84.48%-100.52K | -13.98%-78.76K | -133.34%-44.95K | -77.06%-226.84K | -76.02%-83.98K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 18.89%-81.53K | -43.58%-113.09K | -48.21%-66.62K | -56.35%-354.67K | -55.31%-130.44K | -84.48%-100.52K | -13.98%-78.76K | -133.34%-44.95K | -77.06%-226.84K | -76.02%-83.98K |
| Diluted earnings per share | 0 | 0 | 0 | 0.00%-0.01 | 0 | 0 | 0 | 0 | 0.00%-0.01 | 0 |
| Basic earnings per share | 0 | 0 | 0 | 0.00%-0.01 | 0 | 0 | 0 | 0 | 0.00%-0.01 | 0 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.